links.lww.com/EDE/A980

(1)

eTable 1. Comparison of Sociodemographic Characteristics and Healthcare Utilization Between Stage 2 Participants and Nonrespondents by BCG Vaccination and Asthma Status (n=4800)

BCG⁺ Asthma⁺ BCG⁺ Asthma^- BCG^- Asthma⁺ BCG^- Asthma^-

Stage 2 Participants

N = 446

Non- respondents

N = 754

N = 447

Non- respondents

N = 753

N = 385

Non- respondents

N = 815

N = 365

Non- respondents

N = 835 Sex

Males 165 (37) 346 (46) 201 (45) 399 (53) 157 (41) 410 (50) 160 (44) 442 (53)

Females 281 (63) 408 (54) 246 (55) 354 (47) 228 (59) 405 (50) 205 (56) 393 (47)

% Difference (95% CI)^a 9 (3, 15) 8 (2, 14) 9 (4, 15) 9 (3, 15)

Maternal birthplace Missing = 10 Missing = 14 Missing = 54 Missing = 45

In Québec 428 (97) 723 (96) 435 (98) 710 (96) 324 (89) 620 (79) 297 (84) 618 (77)

Outside Québec 11 (3) 28 (4) 8 (2) 33 (4) 42 (11) 160 (21) 56 (16) 184 (23)

% Difference (95% CI)^a -1 (-3, 1) -2 (-5, -0.5) -9 (-13,-4) -7 (-12, -2)

Paternal birthplace Missing = 47 Missing = 36 Missing = 87 Missing = 82

In Québec 417 (97) 683 (95) 428 (97) 693 (96) 306 (86) 588 (78) 276 (80) 587 (76)

Outside Québec 14 (3) 39 (5) 13 (3) 30 (4) 51 (14) 168 (22) 68 (20) 187 (24)

% Difference (95% CI)^a -2 (-5, 0.4) -1 (-3, 1) -8 (-12, -3) -4 (-9, 1)

Area of residence^b Missing = 91 Missing = 107 Missing = 189 Missing = 215

Rural 76 (17) 129 (19) 96 (22) 166 (26) 57 (15) 110 (18) 56 (15) 122 (20)

Urban 370 (83) 534 (81) 351 (78) 480 (74) 328 (85) 516 (82) 309 (85) 498 (80)

% Difference (95% CI)^a 2 (-2, 7) 4 (-0.9, 9) 3 (-2, 7) 4 (-0.7, 9)

Material and social deprivation index^c Missing = 122 Missing = 120 Missing = 217 Missing = 241

Most privileged on both dimensions 89 (20) 82 (13) 98 (22) 95 (15) 87 (23) 144 (24) 69 (20) 113 (19)

% Difference (95% CI)^a 8 (3, 12) 7 (3, 12) -0.8 (-6, 5) 1 (-4, 6)

Average conditions on both dimensions 113 (26) 134 (21) 98 (22) 128 (20) 109 (29) 115 (19) 93 (26) 128 (21)

% Difference (95% CI)^a 5 (-0.1, 10) 2 (-3, 7) 10 (4, 15) 5 (-0.2, 11)

Least privileged on social dimension only 92 (21) 173 (27) 86 (19) 134 (21) 78 (21) 142 (24) 77 (22) 163 (27)

% Difference (95% CI)^a -6 (-11, -0.6) -2 (-6, 3) -3 (-8, 3) -5 (-10, 0.7)

Least privileged on material dimension only 98 (23) 155 (24) 123 (28) 197 (31) 65 (17) 112 (18) 76 (22) 129 (21)

% Difference (95% CI)^a -2 (-7, 4) -3 (-9, 2) -1 (-6, 4) 0.3 (-5, 6)

Least privileged on both dimensions 44 (10) 98 (15) 38 (9) 83 (13) 39 (10) 92 (15) 37 (10) 74 (12)

% Difference (95% CI)^a -5 (-9, -1) -4 (-8, -0.6) -5 (-9, -0.5) -2 (-6, 3)

Language of correspondence Missing = 91 Missing = 107 Missing = 189 Missing = 215

French 441 (99) 649 (98) 441 (99) 632 (98) 343 (89) 531 (85) 325 (89) 526 (85)

English 5 (1) 14 (2) 6 (1) 14 (2) 42 (11) 95 (15) 40 (11) 94 (15)

% Difference (95% CI)^a -1 (-3, 0.7) -0.8 (-2, 1) -4 (-8, 0.1) -4 (-8, 0.3)

Asthma-related medical visits

≤3 152 (34) 270 (36) - - 128 (33) 279 (34) - -

(2)

eTable 1. Comparison of Sociodemographic Characteristics and Healthcare Utilization Between Stage 2 Participants and Nonrespondents by BCG Vaccination and Asthma Status (n=4800)

BCG⁺ Asthma⁺ BCG⁺ Asthma^- BCG^- Asthma⁺ BCG^- Asthma^-

N = 446

Non- respondents

N = 754

N = 447

Non- respondents

N = 753

N = 385

Non- respondents

N = 815

N = 365

Non- respondents

N = 835

% Difference (95% CI)^a -2 (-7, 4) -1 (-7, 5)

4-7 145 (33) 256 (34) - - 127 (33) 261 (32) - -

% Difference (95% CI)^a -1 (-7, 4) 1 (-5, 7)

>7 149 (33) 228 (30) - - 130 (34) 275 (34) - -

% Difference (95% CI)^a 3 (-2, 9) 0.0 (-6, 6)

Asthma-related hospitalizations

0 399 (90) 645 (86) - - 346 (90) 712 (87) - -

≥1 47 (10) 109 (14) - - 39 (10) 103 (13) - -

% Difference (95% CI)^a -4 (-8, 0) -3 (-6, 2)

Asthma-related medical visits and hospitalizations

≤3 151 (34) 266 (35) - - 126 (33) 273 (34) - -

% Difference (95% CI)^a -1 (-7, 4) -0.8 (-6, 5)

4-7 144 (32) 256 (34) - - 127 (33) 263 (32) - -

% Difference (95% CI)^a -2 (-7, 4) 0.7 (-5, 7)

>7 151 (34) 232 (31) - - 132 (34) 279 (34) - -

% Difference (95% CI)^a 3 (-2, 9) 0.1 (-6, 6)

Allergic diseases-related medical visits and hospitalizations^d

No 151 (34) 271 (36) 263 (59) 490 (65) 122 (32) 243 (30) 198 (54) 490 (59)

Yes 295 (66) 483 (64) 184 (41) 263 (35) 263 (68) 572 (70) 167 (46) 345 (41)

% Difference (95% CI)^a 2 (-4, 8) 6 (0.6, 12) -2 (-8, 4) 4 (-2, 11)

Otolaryngology disorders-related medical visits and hospitalizations^e

No 167 (37) 279 (37) 296 (66) 498 (66) 148 (38) 321 (39) 239 (65) 579 (69)

Yes 279 (63) 475 (63) 151 (34) 255 (34) 237 (62) 494 (61) 126 (35) 256 (31)

% Difference (95% CI)^a -0.4 (-6, 5) -0.1 (-6, 6) 0.9 (-5, 7) 4 (-2, 10)

Compilation based on the Methodological Report from the © Gouvernement du Québec, Institut de la statistique du Québec (STATISTICS QUEBEC), survey on ‘Childhood environment and the development of allergic diseases’, March 2013.

Data presented as n (%).

a Difference between Stage 2 participants and non-respondents for categories presented on the preceding line. Discrepancies between actual percentages and their difference are due to rounding.

b Determined using the second character of subjects’ postal code in 2012 (0: rural, ≠0: urban).

c Based on the address of subjects at interview in 2012.

d Allergic diseases include ICD-9 diagnostic codes 477X (allergic rhinitis), 691X (atopic dermatitis and related conditions), 692X (contact dermatitis and other eczema), 693X (dermatitis due to substances taken internally), 708X (urticaria), 995.3 (other allergies), VO7.1 (need for desensitization to allergens) and V15.0 (Personal history of allergy other than to medicinal agents).

e Otolaryngology disorders include ICD-9 diagnostic codes 372X (conjunctivitis), 461X (acute sinusitis), 466.0 (acute bronchitis and bronchiolitis), 472X (chronic rhinitis), 473X (chronic sinusitis), and 491X (chronic bronchitis).